Dr. Reddy’s Laboratories has introduced South Korean firm HK inno.N Corporation’s acid peptic diseases drug Tegoprazan in India.
Tegoprazan 50 mg has been launched, for acid-related gastrointestinal diseases in the country, under brand name PCAB, Dr. Reddy’s said on Tuesday. This follows a partnership the company forged with HK inno.N Corporation in 2022 to commercialise Tegoprazan in India and select emerging markets.
“Our partnership with HK inno.N Corporation for Tegoprazan brings together complementary strengths to enhance patient access to an innovative molecule that addresses critical gaps in acid peptic disease management and improves outcomes,” CEO-Branded Markets (India and Emerging Markets) M.V. Ramana said. Innovation in gastrointestinal diseases treatment is a key focus area and Dr. Reddy’s has built a strong presence in the space, with a portfolio of well-established brands such as Omez, Razo, and Vono, he said.
A next-generation potassium-competitive acid blocker, Tegoprazan is indicated for treatment of acid peptic diseases such as erosive gastroesophageal reflux disease (GERD), non-erosive gastroesophageal reflux disease (NERD) and gastric ulcer. Recent data indicates that APD affects approximately 38% of the Indian population, the company said in a release.
Tegoprazan is approved in 21 countries, including South Korea and China. It is currently under registration in several countries and has successfully completed Phase-III trial in the U.S., it said.
“We are honoured to introduce Tegoprazan in the Indian market, recognised as one of the world’s most significant pharmaceutical markets,” HK inno.N Corporation CEO Dal-Won Kwak said.
Published – September 16, 2025 08:27 pm IST
